Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC : The Backbone Matters
Errataetall: |
CommentOn: J Thorac Oncol. 2022 Jun;17(6):758-767. - PMID 35183773 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 17(2022), 6 vom: 15. Juni, Seite 739-741 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cortellini, Alessio [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-Bacterial Agents |
---|
Anmerkungen: |
Date Completed 31.05.2022 Date Revised 07.07.2022 published: Print CommentOn: J Thorac Oncol. 2022 Jun;17(6):758-767. - PMID 35183773 Citation Status MEDLINE |
---|
doi: |
10.1016/j.jtho.2022.03.016 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM341459879 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM341459879 | ||
003 | DE-627 | ||
005 | 20231226011829.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jtho.2022.03.016 |2 doi | |
028 | 5 | 2 | |a pubmed24n1138.xml |
035 | |a (DE-627)NLM341459879 | ||
035 | |a (NLM)35623673 | ||
035 | |a (PII)S1556-0864(22)00197-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC |b The Backbone Matters |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.05.2022 | ||
500 | |a Date Revised 07.07.2022 | ||
500 | |a published: Print | ||
500 | |a CommentOn: J Thorac Oncol. 2022 Jun;17(6):758-767. - PMID 35183773 | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Editorial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Comment | |
650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
650 | 7 | |a B7-H1 Antigen |2 NLM | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
700 | 1 | |a Facchinetti, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Derosa, Lisa |e verfasserin |4 aut | |
700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer |d 2006 |g 17(2022), 6 vom: 15. Juni, Seite 739-741 |w (DE-627)NLM169435504 |x 1556-1380 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2022 |g number:6 |g day:15 |g month:06 |g pages:739-741 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtho.2022.03.016 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2022 |e 6 |b 15 |c 06 |h 739-741 |